KCNT1 돌연변이가 확인된 영아 이동성 부분 발작 뇌전증 환아에서의 Quinidine 치료를 시도한 영아 1예 = Quinidine Trial in a Patient with Epilepsy of Infancy with Migrating Focal Seizure and KCNT1 Mutation

다국어 초록 (Multilingual Abstract)

Epilepsy of infancy with migrating focal seizure (MFEI) is an early-onset epileptic encephalopathy characterized by randomly migrating focal seizures and psychomotor deterioration. It is associated with mutations in a variety of genes, with potassium sodium-activated channel subfamily T member 1 (KCNT1) being an example. Previously reported KCNT1 mutations in MFEI are gain-of-function mutations. Therefore, quinidine therapy targeted at reduction of pathologically increased KCNT1 channel-mediated potassium conductance has been proposed as a target treatment for MEFI with KCNT1 mutation. The authors report a case involving a patient with MFEI and a missense mutation in KCNT1 (c.7129G>A; p.Phe346Leu) treated with quinidine therapy. Seizure activity was poorly responsive to quinidine.

참고문헌 (Reference)

1 Yuan A, "The sodium-activated potassium channel is encoded by a member of the Slo gene family" 37 : 765-773, 2003

2 Mikati MA, "Quinidine in the treatment of KCNT1-positive epilepsies" 78 : 995-999, 2015

3 Milh M, "Novel compound heterozygous mutations in TBC1D24cause familial malignant migrating partial seizures of infancy" 34 : 869-872, 2013

4 Freilich ER, "Novel SCN1A mutation in a proband with malignant migrating partial seizures of infancy" 68 : 665-671, 2011

5 Lee G, "Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs" 461 : 402-406, 2009

6 McTague A, "Migrating partial seizures of infancy: expansion of the electroclinical, radiological and pathological disease spectrum" 136 : 1578-1591, 2013

7 Marsh E, "Migrating partial seizures in infancy : expanding the phenotype of a rare seizure syndrome" 46 : 568-572, 2005

8 Coppola G, "Migrating partial seizures in infancy : a malignant disorder with developmental arrest" 36 : 1017-1024, 1995

9 Coppola G, "Malignant migrating partial seizures in infancy : an epilepsy syndrome of unknown etiology" 50 (50): 49-51, 2009

10 De Filippo MR, "Lack of pathogenic mutations in six patients with MMPSI" 108 : 340-344, 2014

11 Milligan CJ, "KCNT1 gain of function in 2 epilepsy phenotypes is reversed by quinidine" 75 : 581-590, 2014

12 Data JL, "Interaction of quinidine with anticonvulsant drugs" 294 : 699-702, 1976

13 Suzuki K, "In vivo genome editing via CRISPR/Cas9 mediated homology-independent targeted integration" 540 : 144-149, 2016

14 Poduri A, "Homozygous PLCB1 deletion associated with malignant migrating partial seizures in infancy" 53 : E146-e150, 2012

15 Ochs HR, "Entry of quinidine into cerebrospinal fluid" 100 : 341-346, 1980

16 Ben-Ari Y, "Effects of seizures on developmental processes in the immature brain" 5 : 1055-1063, 2006

17 Hsu PD, "Development and applications of CRISPR-Cas9 for genome engineering" 157 : 1262-1278, 2014

18 Barcia G, "De novo gain-of-function KCNT1 channel mutations cause malignant migrating partial seizures of infancy" 44 : 1255-1259, 2012

19 Kilpinen H, "Common genetic variation drives molecular heterogeneity in human iPSCs" 546 : 370-375, 2017

20 Ishii A, "A recurrent KCNT1 mutation in two sporadic cases with malignant migrating partial seizures in infancy" 531 : 467-471, 2013